NYSE:EQ - Equillium Stock Price, News & Analysis

+0.27 (+7.09 %)
(As of 09/16/2019 04:00 PM ET)
Today's Range
Now: $4.08
50-Day Range
MA: $3.97
52-Week Range
Now: $4.08
Volume6,488 shs
Average Volume29,071 shs
Market Capitalization$70.89 million
P/E RatioN/A
Dividend YieldN/A
Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$70.89 million
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable

Receive EQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.

Equillium (NYSE:EQ) Frequently Asked Questions

What is Equillium's stock symbol?

Equillium trades on the New York Stock Exchange (NYSE) under the ticker symbol "EQ."

How were Equillium's earnings last quarter?

Equillium (NYSE:EQ) released its quarterly earnings data on Monday, August, 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. View Equillium's Earnings History.

When is Equillium's next earnings date?

Equillium is scheduled to release their next quarterly earnings announcement on Thursday, November 21st 2019. View Earnings Estimates for Equillium.

What price target have analysts set for EQ?

5 analysts have issued 12-month price objectives for Equillium's stock. Their forecasts range from $14.00 to $22.00. On average, they anticipate Equillium's share price to reach $17.75 in the next twelve months. This suggests a possible upside of 335.0% from the stock's current price. View Analyst Price Targets for Equillium.

What is the consensus analysts' recommendation for Equillium?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Equillium.

What are Wall Street analysts saying about Equillium stock?

Here are some recent quotes from research analysts about Equillium stock:
  • 1. According to Zacks Investment Research, "Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States. " (8/15/2019)
  • 2. HC Wainwright analysts commented, "We have assessed Equillium using a risk-adjusted net present value (rNPV) approach driven by a discounted cash flow (DCF) analysis. This yields a $326M total firm value, driven by the future royalty-based revenue from itolizumab in GvHD and asthma. We apply a discount rate of 12% and effective tax rate of 30% to all future cash flows. This translates into a price per share of $14, assuming 22.8M shares outstanding as of mid-2020." (8/13/2019)

Has Equillium been receiving favorable news coverage?

Media headlines about EQ stock have trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Equillium earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Equillium.

Who are some of Equillium's key competitors?

What other stocks do shareholders of Equillium own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Equillium investors own include Diamondback Energy (FANG), AbbVie (ABBV), JPMorgan Chase & Co. (JPM), Keysight Technologies (KEYS), Newfield Exploration (NFX), Snap (SNAP), Alkermes (ALKS), Activision Blizzard (ATVI), Bed Bath & Beyond (BBBY) and Atreca (BCEL).

Who are Equillium's key executives?

Equillium's management team includes the folowing people:
  • Mr. Daniel Mark Bradbury, CEO & Chairman (Age 58)
  • Dr. Stephen Connelly, Chief Scientific Officer & Director (Age 37)
  • Dr. Krishna R. Polu, Chief Medical Officer (Age 46)
  • Mr. Bruce D. Steel C.F.A., Co-Founder, Pres, Chief Bus. Officer & Director (Age 53)
  • Mr. Jason A. Keyes, Chief Financial Officer (Age 48)

When did Equillium IPO?

(EQ) raised $70 million in an initial public offering on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

Who are Equillium's major shareholders?

Equillium's stock is owned by many different of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (8.45%), Vanguard Group Inc. (1.23%), Paloma Partners Management Co (0.12%), BlackRock Inc. (0.10%), Edge Wealth Management LLC (0.04%) and Morgan Stanley (0.04%). View Institutional Ownership Trends for Equillium.

Which institutional investors are selling Equillium stock?

EQ stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Equillium.

Which institutional investors are buying Equillium stock?

EQ stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Paloma Partners Management Co, Edge Wealth Management LLC and Morgan Stanley. View Insider Buying and Selling for Equillium.

How do I buy shares of Equillium?

Shares of EQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Equillium's stock price today?

One share of EQ stock can currently be purchased for approximately $4.08.

How big of a company is Equillium?

Equillium has a market capitalization of $70.89 million. Equillium employs 11 workers across the globe.View Additional Information About Equillium.

What is Equillium's official website?

The official website for Equillium is http://www.equilliumbio.com/.

How can I contact Equillium?

The company can be reached via phone at 858-412-5302.

MarketBeat Community Rating for Equillium (NYSE EQ)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Equillium and other stocks. Vote "Outperform" if you believe EQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel